Images

Filter by

Figure 1 Maternal Cardiac Adaptation in Normal Pregnancy and in Women with Obesity
Figure 1: Maternal Cardiac Adaptation in Normal Pregnancy and in Women with Obesity
Figure 1 Components of Lifestyle and Drug Interventions Clinical Trials That Impact MASLD
Figure 1: Components of Lifestyle and Drug Interventions (Clinical Trials) That Impact MASLD
Figure 2 Placebo corrected Percentage Weight Loss Achieved with Maximum Dose of Anti obesity Pharmacotherapies
Figure 2: Placebo-corrected Percentage Weight Loss Achieved with Maximum Dose of Anti-obesity Pharmacotherapies
Anti obesity Pharmacotherapies in the Asia Pacific Region Approval and Reimbursement Status
Anti-obesity Pharmacotherapies in the Asia-Pacific Region: Approval and Reimbursement Status
Summary of Available Guidelines in the Asia Pacific Region
Summary of Available Guidelines in the Asia-Pacific Region
Anthropometric Measurements to Define Obesity Adopted by Asia Pacific Regions or Countries
Anthropometric Measurements to Define Obesity Adopted by Asia-Pacific Regions or Countries
Figure 1 Prevalence of Obesity in the Asia Pacific Region Based on BMI ≥30 kg m2
Figure 1: Prevalence of Obesity in the Asia-Pacific Region (Based on BMI ≥30 kg/m2 )
Figure 2 Possible Effects of Proprotein Convertase Subtilisin Kexin Type 9 on Non alcoholic Fatty Liver Disease and Related Cardiovascular Disease
Figure 2: Possible Effects of Proprotein Convertase Subtilisin/Kexin Type 9 on Non-alcoholic Fatty Liver Disease and Related Cardiovascular Disease
Figure 1 Mechanisms Potentially Responsible for Endothelial Dysfunction and Atherosclerosis in Non alcoholic Fatty Liver Disease
Figure 1: Mechanisms Potentially Responsible for Endothelial Dysfunction and Atherosclerosis in Non-alcoholic Fatty Liver Disease
Figure 2 Management of Cardiovascular Risk Factors in Individuals with Non alcoholic Fatty Liver Disease
Figure 2: Management of Cardiovascular Risk Factors in Individuals with Non-alcoholic Fatty Liver Disease
Figure 1 Pathophysiological Mechanisms Linking NAFLD and CVD
Figure 1: Pathophysiological Mechanisms Linking NAFLD and CVD
Figure 2 Heart Failure with Preserved Ejection Fraction Pathophysiology Clinical Manifestations and Possible Sites of Intervention
Figure 2: Heart Failure with Preserved Ejection Fraction Pathophysiology, Clinical Manifestations and Possible Sites of Intervention